Éveline Boucher

9.4k total citations · 1 hit paper
118 papers, 3.7k citations indexed

About

Éveline Boucher is a scholar working on Hepatology, Oncology and Surgery. According to data from OpenAlex, Éveline Boucher has authored 118 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hepatology, 55 papers in Oncology and 42 papers in Surgery. Recurrent topics in Éveline Boucher's work include Hepatocellular Carcinoma Treatment and Prognosis (50 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (29 papers) and Colorectal Cancer Treatments and Studies (29 papers). Éveline Boucher is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (50 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (29 papers) and Colorectal Cancer Treatments and Studies (29 papers). Éveline Boucher collaborates with scholars based in France, United States and Germany. Éveline Boucher's co-authors include Jean‐Luc Raoul, Étienne Garin, Karim Boudjéma, Julien Edeline, Yan Rolland, Marc Pracht, Bruno Clément, Laurence Lenoir, Élodie Vauléon and Michel Rayar and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

Éveline Boucher

113 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study

2021 289 citations Riad Salem, Éveline Boucher et al. profile →

Peers

Countries citing papers authored by Éveline Boucher

Since Specialization

Citations

This map shows the geographic impact of Éveline Boucher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éveline Boucher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éveline Boucher more than expected).

Fields of papers citing papers by Éveline Boucher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éveline Boucher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éveline Boucher. The network helps show where Éveline Boucher may publish in the future.

Co-authorship network of co-authors of Éveline Boucher

This figure shows the co-authorship network connecting the top 25 collaborators of Éveline Boucher. A scholar is included among the top collaborators of Éveline Boucher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éveline Boucher. Éveline Boucher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study 2024 ·The Oncologist ·Riad Salem, Étienne Garin, Éveline Boucher, Kirk Fowers, Marnix G. E. H. Lam, Siddharth A. Padia, William Proctor Harris	1
2	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial 2019 ·JMIR Research Protocols ·Nikhil Chauhan, Mary F. Mulcahy, Riad Salem, Al B. Benson, Éveline Boucher, (unknown), David Cosgrove, (unknown), Robert J. Lewandowski, (unknown), Bassel F. El‐Rayes, Jonathan Strosberg, Daniel Y. Sze, Ricky A. Sharma	26
3	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial 2018 ·JMIR Research Protocols ·Nikhil Chauhan, (unknown), Éveline Boucher, David Cosgrove, Julien Edeline, (unknown), Laura Kulik, (unknown), Riad Salem	31
4	Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study) 2017 ·Annals of Oncology ·Julien Edeline, Yann Touchefeu, Boris Guiu, Olivier Farges, David Tougeron, (unknown), Laurence Choné, Boris Campillo‐Gimenez, Marc Pracht, Astrid Lièvre, Samuel Le Sourd, Karim Boudjéma, Étienne Garin, Éveline Boucher	2
5	O-019 SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment 2015 ·Annals of Oncology ·Guy A. Van Hazel, Volker Heinemann, Navesh Sharma, Michael Findlay, Jens Ricke, Marc Peeters, David Pérez, Bridget A. Robinson, A. H. Strickland, (unknown), (unknown), Hendrik Kroening, Ido Wolf, Vinod Ganju, Euan Walpole, Éveline Boucher, Thomas Tichler, Val Gebski, Mark Van Buskirk, Peter Gibbs	0
6	Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma 2015 ·Clinical Nuclear Medicine ·Julien Edeline, Fanny Le Du, Michel Rayar, Yan Rolland, Luc Beuzit, Karim Boudjéma, Tanguy Rohou, Marianne Latournerie, Boris Campillo‐Gimenez, Étienne Garin, Éveline Boucher	48
7	Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors 2014 ·Cancer Chemotherapy and Pharmacology ·Julien Edeline, Laurence Crouzet, Samuel Le Sourd, (unknown), Angélique Brunot, Florence Le Roy, C. Cattenoz, Marianne Latournerie, D Gedouin, Anne Guillygomarc’h, Éveline Boucher	16
8	Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma 2014 ·Journal of Surgical Research ·Laurent Sulpice, Michel Rayar, Bruno Turlin, Éveline Boucher, Pascale Bellaud, Mireille Desille, B. Meunier, Bruno Clément, Karim Boudjéma, Cédric Coulouarn	35
9	A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy 2014 ·Annals of Oncology ·Éveline Boucher, Ірина Давиденко, D. Hadler, Reinhard von Roemeling, Giuseppe Aprile	2
10	An update on liver surgery for cholangiocarcinoma 2013 ·Updates in Surgery ·Karim Boudjéma, Giovanni Battista Levi Sandri, Éveline Boucher, Tanguy Rohou, Michel Rayar, Laurent Sulpice	2
11	Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization 2012 ·European Journal of Nuclear Medicine and Molecular Imaging ·Laurence Lenoir, Julien Edeline, Y. Rolland, Marc Pracht, Jean‐Luc Raoul, Valérie Ardisson, P. Bourguet, Bruno Clément, Éveline Boucher, Étienne Garin	28
12	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma 2011 ·Cancer ·Julien Edeline, Éveline Boucher, Yan Rolland, Élodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean‐Luc Raoul	212
13	Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach 2011 ·Nuclear Medicine Communications ·Étienne Garin, Laurence Lenoir, Yan Rolland, Sophie Laffont, Marc Pracht, H. Mesbah, Philippe Porée, Valérie Ardisson, P. Bourguet, Bruno Clément, Éveline Boucher	24
14	New drugs for the treatment of hepatocellular carcinoma 2009 ·Liver International ·Éveline Boucher, Alejandro Forner, María Reig, Jordi Bruix	17
15	Adjuvant Intraarterial Injection of ¹³¹I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up 2008 ·Journal of Nuclear Medicine ·Éveline Boucher, Guillaume Bouguen, Étienne Garin, Anne Guillygomarc’h, Karim Boudjéma, Jean‐Luc Raoul	23
16	A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer 2007 ·Annals of Oncology ·Y. Bécouarn, Pierre Sénesse, Simon Thézenas, Éveline Boucher, Antoine Adenis, Laurent Cany, J H Jacob, F. Cvitkovic, C. Montoto-Grillot, Marc Ychou	11
17	Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) 2007 ·Journal of Clinical Oncology ·Sandrine Faivre, Éric Raymond, Jean‐Yves Douillard, Éveline Boucher, Ho Yeong Lim, Kim Js, Silvana Lanzalone, M.J. Lechuga, Laurie Sherman, Ann‐Lii Cheng	49
18	Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma 2006 ·Radiotherapy and Oncology ·Éveline Boucher, Étienne Garin, (unknown), Damien Olivié, Karim Boudjéma, Jean‐Luc Raoul	26
19	Tonsillar metastasis revealing signet-ring cell carcinoma of the rectum 2005 ·Gastroentérologie Clinique et Biologique ·Élodie Vauléon, Anne‐Sophie de Lajarte‐Thirouard, Éveline Boucher, É. Le Prisé, (unknown), Jean‐Luc Raoul	9
20	Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen) 2002 ·Cancer Chemotherapy and Pharmacology ·Éveline Boucher, (unknown), Pierre Brissot, Karim Boudjéma, Jean‐Luc Raoul	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact